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Purpose: The cancer stem cell hypothesis states that the capacity of a cancer to grow and propagate is dependent on a small 
subset of cells. To determine the significances of the cancer stem cell markers CD133, CD44, and CD24 using a comparative 
analysis with a focus on tumorigenicity. Methods: Four pancreatic cancer cell lines, Capan-1, Mia-PACA-2, Panc-1, and 
SNU-410 were analyzed for the expressions of CD133, CD44, and CD24 by flow cytometry. The tumorigenicity was com-
pared using tumor volumes and numbers of tumors formed/numbers of injection in nonobese diabetic severe combined defi-
ciency mice. Fluorescence-activated cell sorting (FACS) analysis was used to confirm that xenograft explants originated from 
human pancreatic cancer cells. Results: CD133 was positive in only Capan-1, CD44 positive in all, CD24 partially positive in 
Panc-1. After injecting 2 × 10
6 cells, all mice administered Capan-1 or Mia-Paca-2 developed tumors, 3 of 5 administered 
Panc-1 developed tumors, but no mouse administered SNU-410 developed any tumors. The volumes of Capan-1 tumors 
were seven times larger than those of Mia-Paca-2 tumors. When 2 × 10
5 or 2 × 10
4 of Capan-1 or Mia-Paca-2 was injected, tu-
mors developed in all Capan-1 treated mice, but not in Mia-Paca-2 treated mice. Furthermore, xenograft explants of Capan-1 
expressed CD133＋CD44＋  and Capan-1 injected mice developed lung metastasis. FACS analysis showed that xenograft ex-
plants originated from human pancreatic cancer cell lines. Conclusion: CD133 positive cells have higher tumorigenic and 
metastatic potential than CD44 and CD24 positive cells, which suggests that CD133 might be a meaningful cell surface mark-
er of pancreatic cancer stem cells.
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INTRODUCTION
Pancreatic cancer is the ninth most common malignant 
disease, and is the fifth ranked cause of cancer death in 
South Korea. Furthermore, advances in surgical and medi-
cal therapies have had little impact on the mortality rate of 
pancreatic cancer, and its 5-year survival rate after cura-
tive resection remains dismally low at 10 to 15%. In addi-
tion, the mechanisms of local tumor invasion and an early 
systemic dissemination at the molecular level in pancre-
atic cancer have not been completely elucidated. 
The cancer stem cell (CSC) hypothesis may provide an 
understanding of cancer development and progression, 
and a new perspective as to how to develop therapies to 
treat cancer. CSCs constitute only a small proportion of 
cancer cells and are capable of self-renewal, differentia-
tion, and tumorigenesis [1]. Research on the existence of 
CSCs was first undertaken in the context of human acute 
myeloid leukemia. However, recently studies on the cell 
surface marker expressions of CSCs, such as, CD133, 
CD44, CD24, and epithelial-specific antigen (ESA), have 
reported their involvements in solid malignancies of the 
breast, brain, prostate, and ovary [2-9]. 
To date, little study has been conducted on CSCs in pan-
creatic cancer, and thus, we undertook to determine the 
significances of cell surface markers, namely, CD133, 
CD44, and CD24, on the CSCs of pancreatic cancer cells. 
METHODS
Cell culture
The pancreatic cell lines Capan-1, Mia-Paca-2, and 
Panc-1 were obtained from the American Type Culture 
Collection (Manassas, VA, USA), and SNU-410 was ob-
tained from the Korean Cell Line Bank (Seoul). All four cell 
lines were cultured in Roswell Park Memorial Institute 
medium supplemented with 10% fetal bovine serum 
(FBS). Explants obtained from nonobese diabetic severe 
combined immunodeficient (NOD-SCID) mice injected 
with each of the pancreatic cell lines were cultured in the 
Dulbecco’s modified eagle medium F12 (DMEM/F12) 
(Hyclone Laboratories Inc., Lakewood, NJ, USA) supple-
mented with 10% FBS. All pancreatic cell lines originated 
from the pancreas, and of the four, only Capan-1 was origi-
nated from a patient with pancreatic cancer and hepatic 
metastasis. 
Flow cytometry
For surface marker analysis by flow cytometry, cells 
were dissociated using trypsin- ethylenediaminetetra-
acetic acid (EDTA) (trypsin 0.25%; EDTA 0.02%) for 2 to 5 
minutes at 37
oC, transferred to a 5-mL tube, and washed 
twice with PBS. Cells were then resuspended in PBS con-
taining 0.1% sodium azide and 2% FBS, anti-human 
CD133-PE, anti-human CD24-PE, and anti-human CD44- 
FITC (BD Bioscience, San Jose, CA, USA) were then added, 
and cells were incubated at 4
oC for 20 minutes and washed 
twice with PBS. Rat anti-mouse immunoglobulin G (IgG)- 
fluorescein isothiocyanate (FITC) and Rat anti-mouse 
IgG-PE were used as isotype controls (BD Biosciences). 
The origins of explants obtained from xenograft tissues 
were confirmed by staining with anti-HLA-ABC-FITC 
(human histocompatibility class I) and anti-H2K-FITC 
(mouse histocompatibility class I) (BD Bioscience). Dead 
cells were gated out by propidium iodide (5 μg/mL) 
staining. Flow cytometry was performed on a FACS, and 
data were analyzed using Cell Quest software (BD 
Bioscience).
In vivo animal studies
NOD/SCID mice (aged 6 to 8 weeks) were obtained 
from Jackson Laboratory (Bar Harbor, ME, USA) and 
raised under specific pathogen free conditions (Laborato-
ry Animal Research Center, Samsung Medical Center, 
Seoul).
Single cells from each of the four cell lines were re-
suspended in 50 μL of PBS, and then injected (2 × 10
6 to 2 × 
10
4  cells/injection) into the right kidney capsules of 
NOD/SCID mice. Animals underwent autopsy 6 weeks af-
ter implanting 2 × 10
6 cells. In subsequent studies on 
Capan-1 and Mia-Paca-2, autopsies were performed 12 
weeks after implanting 2 × 10
4 or 2 × 10
5 cells (Fig. 1). 
During autopsies tumor dimensions and volumes, and the 
presence of any metastatic lesion were noted. Tissues were 
fixed in formaldehyde and hematoxylin and eosin stain CD133 as a surface marker of pancreatic cancer stem cells
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Fig. 1. Overall process of animal study. Animals underwent 
autopsy 6 weeks after implanting 2 × 10
6 c e l l s .  I n  s u b s e q u e n t 
studies on Capan-1 and Mia-Paca-2, autopsies were performed 12 
weeks after implanting 2 × 10
4 or 2 × 10
5 cells.
Fig. 2. Capan-1 highly expresses 
CD133 but other cell lines, Panc-1, 
Mia-Paca-2, SNU-410 express less 
than 2% of CD133. Panc-1 expresses 
30% of CD24 and CD44 double 
positive but other cell lines express 
less than 10% of CD24. Most cell 
lines are CD44 positive.
for histologic examinations. In addition, tumor cells from 
xenografts were confirmed to have originated from the 
human pancreatic cancer cell lines by FACS. Mice tumors 
were chopped with a sterile scalpel blade over ice to 2 to 3 
mm pieces, transferred to 50 mL tubes, collagenase (1 
mg/mL) was then added, and samples were incubated at 
37
oC for 1 hour in a shaking incubator. Isolated cells were 
cultured in Dulbecco's modified Eagle's medium 
(DMEM)/F12 supplemented with 10% FBS and harvested 
at passage 1 for FACS analysis.
RESULTS
Cell surface markers
Cell surface marker expressions were analyzed by 
FACS. As shown in Fig. 2, 76.5% of Capan-1 cells ex-
pressed the cell surface marker CD133, 94% expressed 
CD44, and 6.9% expressed CD24. For Panc-1, Mia-Paca-2, 
and SNU-410, few cells were positive for CD133, 94 to 
99.9% was positive for CD44, and Panc-1 alone was weakly 
positive (31.9%) for CD24. Capan-1 was CD133＋CD44＋
CD24－, Mia-Paca-2 CD133－CD144＋CD24－, Panc-1 Hyun Joo Lee, et al.
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Table 1. Relationships between cell surface marker expression and 
tumorigenicity in human pancreatic cancer cell lines 
Cell line CD133 CD44 CD24 Tumorigenicity
Capan-1 ＋ ＋ － ＋＋＋＋
Mia-Paca-2 －＋ ＋－ ＋ ＋
Panc-1 －＋ ＋ ± ＋
SNU410 －＋－ －
Table 2. Number of tumor-bearing mice per total severe 
combined immunodeficient mice implanted with pancreatic 
cancer cell lines 
Cell No. Cell line Tumorigenicity
Lung 
metastasis
Time (wk)
2 × 10
6 Capan-1 5/5 4/5 6
Mia-Paca-2 5/5 0/5
Panc-1 3/5 0/5
SNU410 0/5 0/5
Fig. 3. CD133+ Capan-1 generates a 
significant tumor growth compared 
with other CD133– cell lines (A, B). 
Microscopic finding of xenograft 
explants of 3 pancreatic cell lines 
except SNU-410 (C).
CD133CD44＋CD24± and SNU-410 CD133－CD44＋
CD24－  (Table 1).
Tumorigenicity
To compare tumorigenicities, 2 × 10
6 cells of each pan-
creatic cell line were injected into NOD/SCID mice (n = 5 
per cell line). During autopsy at 6 weeks post-injection, all 
five mice injected with Capan-1 or Mia-Paca-2 developed 
tumors, whereas 3 of 5 mice injected with Panc-1 and no 
mouse injected with SNU-410 developed as tumor. 
However, Capan-1 tumor volumes were seven times larg-
er than Mia-Paca-2 tumor volumes (Table 2, Fig. 3). In or-
der to identify differences between Capan-1 and Mia- 
Paca-2, NOD/SCID mice were injected with 2 × 10
5 or 2 × CD133 as a surface marker of pancreatic cancer stem cells
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Table 3. Number of tumor-bearing mice and metastatic mice per 
total severe combined immunodeficient mice implanted with 
pancreatic cancer cells
Cell No. Cell line Tumorigenicity
Lung 
metastasis
Time (wk)
2 × 10
5 Capan-1 4/4 2/4 12
Mia-Paca-2 0/4 0/2
2 × 10
4 Capan-1 4/4 0/4 12
Mia-Paca-2 0/4 0/4
Fig. 4. Tumor formation ability of CD133＋  Capan-1 and CD133－  Mia-Paca-2 cells were compared after decreasing of number of injected cells.
All 133
＋ Capan-1 cells formed tumors in kidney, whereas no CD133－  cell could form tumor. (A, B) Only CD133＋  Capan-1 had metastasis 
to the lung.
10
4  cells (n = 4 per group) and sacrificed 12 weeks 
post-injection. In mice injected with 2 × 10
5 or 2 × 10
4 
Capan-1 cells, all 8 mice developed tumors, where no tu-
mor developed in Mia-Paca-2 injected mice. In addition, 
metastasis to the lung occurred in Capan-1 treated mice, 
whereas no metastasis was observed in mice injected with 
the other cell lines (Table 3, Fig. 4).
Origins of xenograft explants
Although tumors grown probably originated from the 
human pancreatic cancer cell lines, it was possible that 
mice cells could have infiltrated tumors and developed in-
to xenografts. Thus, FACS was used to confirm that xeno-
graft explants obtained originated from the human pan-
creatic cancer cells. Tumor cells in explants were found to 
be positive for HLA-ABC but negative for H2K-BDK, in-
dicating that mice cells had not infiltrated tumors. 
Furthermore, the expressions of cell surface markers in ex-
plants were identical to those of the parent cancer cell lines 
(Fig. 5).
DISCUSSION
Stem cells reside at the apex of the hierarchical structure 
that describes the generation of mature cells for particular Hyun Joo Lee, et al.
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Fig. 5. Characteristics of xenograft explants according to Fluore-
scence-activated cell sorting analysis. Xenograft explants was also 
CD133＋CD44＋ as similar with primary Capan-1. Xenograft 
explants was positive against anti-HLA-ABC (human histocom-
patibility class I) but negative against anti-H2K (mouse histo-
compatibility class I) (bottom).
organs through differentiation. Stem cell biology studies 
provide an insight into cancer biology, and have led to new 
approaches in the fight against malignant disease. CSCs 
are rare, have indefinite self-renewal potential, and drive 
tumorigenesis. In addition, like their normal stem cell 
counterparts, CSCs are well suited to survive adverse con-
ditions in the tissue microenvironment [1,10,11]. Recently, 
it was reported that CSCs are present in acute leukemia 
[3,6], and in solid malignancies, such as, breast [2], brain 
[4,5,8], prostate [7] and ovary cancer [9].
Bonnet and Dick [3] first isolated CSCs in myeloid leu-
kemia by using cell surface marker expression and the 
ability of human leukemia cells to engraft in NOD/SCID 
mice. The FACS and establishment of human tumor xeno-
graft models in NOD/SCID mice, are important research 
tools for studies on CSCs [3,12]. Al-Hajj et al. [2] identified 
CSCs in breast cancer using these tools. They reported that 
small subset of tumor cells with CD44＋CD24－/low epi-
thelial-specific antigen (ESA)＋ cell surface marker ex-
pression had strong tumorigenicity. Regarding pancreatic 
cancer cells, heterogeneous surface marker expression for 
CD44, CD24, and ESA was demonstrated by FACS. These 
cell surface markers had been shown to be CSC surface 
markers in previous studies, and are believed to act as ad-
hesive molecules with various signaling functions [13-17]. 
Li et al. [18] sorted pancreatic cancer cells for CD44, CD 24, 
and ESA individually and in combination, and reinjected 
sorted cells into NOD/SCID mice. It was found that cells 
expressing CD44＋CD24＋ESA＋  comprised only 0.2% to 
0.8% of all human pancreatic cancer cells, but had highest 
tumorigenicity. In the present study, some CD44＋CD24＋ 
cell (Mia-Paca-2, Panc-1) also developed tumor after 2 × 10
6 
cells injection, however, when cells of 2 × 10
5 or 2 × 10
4 was 
injected no tumor developed. The cell line study may be 
the cause of difference compared with the study using 
pancreatic adenocarcinoma specimen by Li et al [18].
The surface marker CD133 was first reported to have the 
properties of CSCs in brain and colon cancer [8,19,20]. 
Hermann et al. [21] demonstrated that CD133＋  cells con-
stituted only 1 to 3% of pancreatic adenocarcinoma cells, 
and found that 500 cells injected in NOD/SCID mice were 
able to generate tumors. In the literature, two types of 
CSCs expressing CD44/CD24/ESA or CD133 are present in 
pancreatic cancer, such findings raise questions regarding 
the number of types of CSCs and which types have greater 
tumorigenic potential. Wright et al. investigated this issue 
in breast cancer and found two distinct types of CSCs ex-
pressing CD44＋/CD24－ or CD133＋ and no overlap of 
surface marker expression. In addition, CSC expressional 
types have been reported to have similar tumorigenicities 
[22]. In a study of pancreatic cancer cells, Hermann et al. 
[21] reported an overlap of 14% between CD44＋CD24＋
ESA＋ and CD133＋ pancreatic cancer cells, but un-
fortunately, no comparison of tumorigenicity was made. 
Further in vivo tumorigenicity experiments will need to be 
performed to ascertain if CD44＋CD24＋ESA＋ and 
CD133＋ pancreatic cancer cells represent distinct CSC 
populations, or if a pancreatic cancer cell population ex-CD133 as a surface marker of pancreatic cancer stem cells
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pressing combination of markers is more enriched for CSC 
function [12,21]. 
In the present study, we analyzed pancreatic cancer cell 
lines as for the expressions of CD133, CD44, and CD24, 
that is, all of the known cell surface markers of CSCs, and 
these cell lines were also compared with respect to 
tumorigenicity. Capan-1, which metastasizes to the liver, 
was only positive for CD133 and CD44 and these two 
markers may be expressed in the same CSC populations. 
We performed in vivo experiments on tumorigenicity and 
found that CD133 positive cells had the highest tumori-
genic potential and high rates of metastasis to the lung 
compared with CD44 positive cells, which suggests that 
CD133 represents the aggressive behavior of pancreatic 
cancer. Comparative analysis between CD133 positive 
cells and CD133 negative cells after sorting from each pan-
creatic cancer cell lines will support this study and is plan-
ned in our labroatory. Hermann et al. [21] suggested that 
human pancreatic cancer tissue contains CD133 express-
ing CSCs that are exclusively tumorigenic and associated 
with metastatic potential. 
In the present study, we failed to establish human pa-
tient pancreatic cancer xenograft models in NOD/SCID 
mice, and subsequently switched to pancreatic cancer cell 
lines. After single cell isolation from human pancreatic 
cancer tissue, cell was failed to be cultured in vitro. Further 
research with enough tumor mass is needed to set the mi-
croenvironment for in vitro cell culture. However, we real-
ized during the course of this study that animal host cells 
could infiltrate the tumor. Therefore, we caution that the 
possibility that xenograft explants have been infiltrated by 
mice cell should be routinely checked-up by using FACS 
analysis or karyotyping. 
Summarizing, the present study demonstrates: 1) 
CD133 positive cells had a higher tumorigenic potential 
than cells expressing CD44, or CD24; 2) Only CD133 pos-
itive cells were associated with metastasis to the lung; 3) 
the tumorigenicity of CD133＋ cells was maintained by 
even a small number of injected cells; and 4) Xenograft ex-
plants that developed after injecting CD133＋ cells were 
confirmed to have originated from human pancreatic can-
cer cells and found to maintain CD133 expression. We sug-
gest that these findings be re-evaluated in freshly retrieved 
human specimens. Furthermore, our findings suggest that 
CD133 may be potentially an important cell surface mark-
er of pancreatic cancer stem cells, and that it may be used 
as a molecular target for the development of treatments for 
intractable pancreatic cancer.
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